Gild Gilead's purchase of Kite Pharma poised to pay off Gilead Sciences Inc.'s $11 billion bet on Kite Pharma Inc. is poised to pay off, with the approval Wednesday of Kite's flagship cell-therapy treatment for advanced lymphoma patients. The therapy, known as a Car-T treatment, uses genetically engineered T-cells to attack the blood cancer. It is the second such therapy to get a regulatory green light, after Novartis AG's (NOVN.EB) Car-T drug Kymriah was approved in late August.
earnings the 26 estimates increasing during the quarter
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.